Pay in 4 interest-free payments of $6.31 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Try eating in smaller amounts and take your time chewing
FDA approval for obstructive sleep apnea In December 2024, the FDA approved tirzepatide (marketed as Zepbound) for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity
The medications now target multiple organ systems, including the pancreas, stomach, brain, heart, kidneys, immune system, skeletal muscle, adipose tissue, and liver, addressing multiple chronic conditions simultaneously rather than just treating obesity
Two main classes exist: GHRH analogs (CJC-1295, Tesamorelin): These mimic growth hormone-releasing hormone, activate GHRH receptors on pituitary, and stimulate GH synthesis and release
The results showed that tirzepatide led to greater reductions in HbA1c levels, fasting serum glucose, and body weight compared to placebo or a selective GLP-1 receptor agonist
Our digital transformation triple aim: improve affordability, improve experience, maximize digital process automation.SarahKay Hermosillo SarahKay Hermosillo 3yBryce Williams shared thisJust rounded up speaking at the 2023 BCBS Western Operations Conference, where I shared highlights on our teams strategic objectives for improving member experience
